February 26, 2024 10:42 AM EST

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Milestone Pharmaceuticals details plan to resubmit etripamil to the FDA in Q2: For its experimental treatment for paroxysmal supraventricular tachycardia, the company

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Mile­stone’s plans to re­sub­mit heart drug; Alvotech’s $166M of­fer; Vac­cine biotech rais­es $11M

Deputy Editor

Senior Reporter

Sign up to read this article for free.

Milestone’s plans to resubmit heart drug; Alvotech’s $166M offer; Vaccine biotech raises $11M